CA-WHITE-OAK-GLOBAL
25.8.2021 14:32:11 CEST | Business Wire | Press release
White Oak Global Advisors ("White Oak") is pleased to welcome Jon Patty as a Managing Director and a partner based in the San Francisco office. Mr. Patty joins White Oak’s Head of ESG & Impact, Terésa Cutter, and is responsible for leading new ESG and Impact-oriented investment opportunities and strategies, as well as working closely with White Oak’s clients and borrowers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005213/en/
Mr. Patty is an accomplished impact investor with a successful background investing in private equity, private credit, structured debt, and sustainable infrastructure. Over the course of his twenty year investment career, Mr. Patty has partnered with senior executives across sectors and served on numerous boards of directors to help drive both compelling impact outcomes and strong financial results.
Mr. Patty most recently served as Managing Director and Head of Private Equity at New Island Capital, one of the largest institutional-scale, global impact investment firms, for 10 years. Prior to that, he worked for MC Partners, a $1.5 billion private equity firm, and JPMorgan Capital, then a $4 billion private equity effort. Mr. Patty previously worked in strategic management consulting at Bain & Co. and in investment banking at JPMorgan.
“We are excited to welcome Jon to the team,” said Andre Hakkak, CEO and co-founder of White Oak. “His deep expertise and proven track record in supporting the growth of mission-driven businesses complement White Oak’s dedication to partnering with strong management teams who aspire to the highest ESG standards while building high quality, financially rewarding businesses.”
“I am thrilled to join a world-class organization with a commitment to driving strong social and environmental outcomes with its partners, and I look forward to bringing White Oak’s impact perspective and customized product offerings to mission-driven companies,” said Mr. Patty. “White Oak has a track record of leading creative, flexible financings using a partnership-driven approach, and now has the opportunity to help companies implement the highest ESG standards, deepen their impact, and extend their financial success.”
White Oak (together with and through its financing affiliates) has a track record of over $3.8 billion in ESG-aligned investments since inception. White Oak's impact strategy focuses on secured loan lending to small and medium sized companies committed to providing products and services that create positive environmental and social impact while building economically sustainable businesses.
About White Oak Global Advisors
White Oak Global Advisors, LLC is a leading global alternative asset manager specializing in originating and providing financing solutions to facilitate the growth, refinancing and recapitalization of small and medium enterprises. Since its inception in 2007, White Oak Global Advisors’ disciplined investment process focuses on delivering risk-adjusted investment returns and establishing long term partnerships with our borrowers. For more information, visit www.whiteoaksf.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005213/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay17.3.2026 07:00:00 CET | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Neurofilament light chain (NfL) in plasma and serum. “While our assay menu already features many powerful disease-specific biomarkers, NfL marks a major breakthrough: our first CE-marked blood test that empowers clinicians with insights across a wide range of neurological disorders,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “We are excited to bring this test to our customers, further expanding our comprehensive portfolio of fully automated neurological disease testing solutions on the LUMIPULSE G platform. We continue to partner with organizations and clinical experts across the wor
H2SITE Appoints Javier Cavada as New Chairman of the Board of Directors17.3.2026 07:00:00 CET | Press release
H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316654723/en/ With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, building high-performance organisations, and scaling large-scale energy platforms. He currently serves as President and Chief Executive Officer of Mitsubishi Power EMEA. His track record also includes serving as CEO and President of Highview Power, as well as spending 17 years at Wärtsilä Corporation, where he held senior executive roles including President of the Energy division and a member of the global Exec
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies17.3.2026 07:00:00 CET | Press release
Galderma will present nine posters spanning its full aesthetics portfolio at AMWC 2026, highlighting the regenerative benefits of Sculptra®, the long-lasting efficacy of Restylane®, and the advanced clinical performance of Relfydess® (RelabotulinumtoxinA) 1-9 The data reinforce Galderma’s future-focused approach to innovation, addressing emerging patient needs from menopause‑related skin changes to rising interest in body injectables and regenerative treatments A series of symposia and Masterclasses will further highlight Galderma’s leadership in aesthetics, showcasing how the portfolio supports complex patient profiles and evolving global trends Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra, R
Miro Announces Asia Hub in Singapore to Accelerate Growth Across the Region and Bring AI Collaboration to New Markets17.3.2026 02:00:00 CET | Press release
AI Innovation Workspace perfectly placed to help organisations maximise AI investment and accelerate innovation Miro®, the AI Innovation Workspace for teams, today announced plans to expand its operations in Asia, supporting organisations across the region in their AI transformation journey. Miro is investing in people, resources, and infrastructure as it targets growth in key markets, including Singapore, India, South Korea, and other Southeast Asia countries. As the global innovation centre of gravity shifts toward Asia – where R&D spending reached 45% of global investment in 2024 – the organisations leading this charge need tools and platforms built for the complexity and pace of modern innovation and collaboration. Miro's AI-powered innovation workspace is uniquely positioned to support this moment. Miro gives organisations the shared context layer they need to move from insight to execution faster than ever before. For Asia's most ambitious innovators, where speed-to-market and cr
IQM and Zurich Instruments Launch Real-Time Quantum Error Correction Demonstrator with NVIDIA NVQLink16.3.2026 22:24:00 CET | Press release
The demonstrator being built in this project delivers a clear path toward scalable and fault-tolerant quantum computers. The joint project integrates IQM’s superconducting quantum processor, Zurich Instruments’ ZQCS Quantum Control System, with the NVIDIA NVQLink platform to enable real-time error correction. This initiative establishes a foundation for standardized enterprise-ready quantum systems, and datacenter deployment. Today, IQM Quantum Computers and Zurich Instruments announce a joint project to build and operate a real-time quantum error correction (QEC) demonstrator, enabled by the NVIDIA NVQLink platform. This project marks a significant milestone toward scalable and fault-tolerant quantum computing designed for enterprise and datacenter deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316511715/en/ IQM and Zurich Instruments launch real-time quantum error correction demonstrator with NVIDIA NVQLink
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom